Latest Hotspot

EMA Accepts Submission for Linvoseltamab as Therapy for Recurrent/Resistant Multiple Myeloma

11 February 2024
3 min read

Regeneron Pharmaceuticals, Inc. has disclosed that the European Medicines Agency is currently examining their submitted Marketing Authorization Application, which pertains to the therapeutic agent linvoseltamab. This treatment is specifically designed for use in adult individuals who are battling relapsed or resistant multiple myeloma, and have experienced further disease progression following a minimum of three previous treatment attempts.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen 

Linvoseltamab is a novel bispecific antibody under research that has been engineered to connect the B-cell maturation antigen (BCMA) found on multiple myeloma cells to T cells containing the CD3 receptor. This connection is meant to prompt the activation of T cells and the subsequent destruction of the cancerous cells.

Data underpinning the MAA involve results from a preliminary Phase 1/2 key study focused on assessing linvoseltamab for patients with relapsed or refractory multiple myeloma (R/R MM). These findings were disclosed in the final month of 2023. Concurrently, a Biologics License Application for linvoseltamab was lodged with the FDA that same December.

As a major hematological malignancy, multiple myeloma accounts for over 176,000 fresh diagnoses worldwide each year. The disease primarily consists of abnormal plasma cells multiplying and outcompeting normal blood cells in the bone marrow, while also spreading to and compromising other body tissues, risking severe organ damage. Despite medical progress, MM remains an incurable illness. Though existing therapies can decelerate its advancement, the majority of patients will nonetheless see their illness progress and will be in need of further treatment options.

Within the clinical studies for linvoseltamab, an ongoing Phase 3 confirmatory trial is actively recruiting participants. 

Further research efforts are either organized or in the process, aiming to explore treatment in initial therapy sessions and different stages of the disease. This includes a Phase 1/2 study for first-line therapy, a Phase 2 study for patients with high-risk smoldering multiple myeloma, and another Phase 2 study focusing on monoclonal gammopathy of undetermined significance. Moreover, there are plans for a Phase 1 study that will test linvoseltamab alongside a CD38xCD28 costimulatory bispecific antibody in multiple myeloma patients.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of February 8, 2024, there are 31 investigational drugs for the BCMA and CD3 target, including 15 indications, 50 R&D institutions involved, with related clinical trials reaching 108, and as many as 6676 patents.

Linvoseltamab is a bispecific antibody drug targeting BCMA and CD3, primarily indicated for relapsed/refractory multiple myeloma. Its originator organization is Regeneron Pharmaceuticals, Inc., and it is currently in the NDA/BLA phase. The drug's potential therapeutic areas extend beyond multiple myeloma, but further research is needed to explore its efficacy and safety in these areas. Monitoring its progress and regulatory approvals will be crucial for assessing its impact on the pharmaceutical industry and patients.

图形用户界面, 文本, 应用程序

描述已自动生成

Effortless Searching: How to Find Methylphenidate on Synapse
Drug Insights
2 min read
Effortless Searching: How to Find Methylphenidate on Synapse
11 February 2024
Methylphenidate hydrochloride is a leading CNS stimulant, first approved by the US on December 5, 1955, and developed by Novartis. It effectively treats narcolepsy, ADD, and ADHD.
Read →
4DMT's Study Shows Promising Outcomes for Eye Injection 4D-150 in Treating Wet Age-Related Macular Degeneration
Latest Hotspot
3 min read
4DMT's Study Shows Promising Outcomes for Eye Injection 4D-150 in Treating Wet Age-Related Macular Degeneration
11 February 2024
4DMT Unveils Encouraging Early Results of the Phase 2 PRISM Study for the Eye Injection 4D-150, Indicating Good Safety and Efficacy in Treating Wet Age-Related Macular Degeneration.
Read →
Making the Most Out of Synapse: Searching for Carvedilol
Drug Insights
2 min read
Making the Most Out of Synapse: Searching for Carvedilol
11 February 2024
Carvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990.
Read →
Inmagene Activates Its Right to Secure Sole Global Licensing for IMG-007 and IMG-004 from HUTCHMED
Latest Hotspot
3 min read
Inmagene Activates Its Right to Secure Sole Global Licensing for IMG-007 and IMG-004 from HUTCHMED
11 February 2024
Inmagene Biopharmaceuticals has announced its intention to acquire a solo, global license with royalties for IMG-007, a non-eliminating humanized antibody targeting OX40, and IMG-004, a systemically administered BTK inhibitor with non-covalent, reversible mechanisms.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.